Aequus Pharmaceuticals Inc.
AQSZF
$0.003
-$0.0009-23.08%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.78% | 4.31% | 10.76% | 30.02% | -56.20% |
| Total Depreciation and Amortization | -6.18% | -6.56% | -4.67% | -2.73% | 6.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.08% | -27.69% | 6.21% | -96.55% | 211.85% |
| Change in Net Operating Assets | 136.29% | -158.85% | -79.91% | -372.99% | 299.69% |
| Cash from Operations | 47.21% | -45.89% | -96.05% | -101.61% | -17.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -51.70% | 10.00% | 535.40% | -- | -- |
| Total Debt Repaid | -8.55% | -8.55% | -8.55% | 41.62% | -2.39% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -55.62% | 8.12% | 869.60% | 1,508.78% | 1,986.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.50% | -1,304.85% | 135.07% | 111.29% | 113.78% |
